Skip to Content

Pembrolizumab in first-line therapy improves survival independent of PD-L1 expression and brain metastases in patients with NSCLC

Get access to the article

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top